Webinar by John Lux in April 2009 — at the bottom.

This webinar was done in 2009, near the market’s low.

Volatility creates opportunity.

That is the secret — people are using volatility to scare you.

People who do not like volatility are telling you that they do not know how to trade.

When prices are too high, you sell, when too low you buy, duh.

So you look for when prices shoot up and then hit the wall. The price will trace out for you where the resistance is after a few days or a week or so. Just be patient and watch until the price pattern reveals where the buyers and sellers are.

You can also trade spikes. If the spike goes too far, you act.

Go for it!

OTC Pink: GATA   $0.64

______

October 11, 2011

Our Recommendation: Strong Speculative Buy

We first recommended that you buy GATA on June 6, when the stock was $0.21 bid. Since then it has sold as high as $1.03 and a large inflow of new orders has been received by GATA.

Yesterday, there was an announcement by GATA of the results for the quarter ended on September 30. Sales and earnings are running ahead of our expectations and we again recommend that suitable speculative accounts buy GATA.

As the stock gets more recognition, we expects its P/E to outstrip the larger companies in the industry. As it stands now, GATA is extremely under-priced compared to others in the contract research industry, especially when you consider that its growth rate is much higher.

Company                                                Symbol     Price                 Trailing P/E           Forward P/E

Covance                                                  CVD           46.64                 43.07                        14.13

Pharmaceutical Prod Dev               PPDI            32.24                22.59                        17.43

Charles River                                        CRL            29.01                N/A                          10.67

Parexel Corp.                                       PRXL          20.83                 25.72                      13.44

Icon plc                                                  ICLR           15.40                  15.14                      12.73

Groupe Athena                                   GATA            0.64                  14.22                       5.33

We expect the P/E held by GATA to eventually expand to a level higher than that of the other contract research organizations. Going from a forward-looking P/E of 5.33 to 15 or better would increase the stock price level considerably. Add that to the high growth rate commanded by GATA and you can start to vividly imagine the potential we see in GATA.

Again, we believe that the more you look at our earnings model for GATA, the more you can find yourself solidly grasping the future that would cause you to buy GATA stock now. GATA may continue its near 100% annual growth rate and 10% net earnings ratio for the next few years due to an explosion in a market where it has a strong geographical advantages, first mover advantages, and technical advantages.

More informaton on GATA is available at www.gatareport.com
Disclaimers

This is a very speculative stock traded at in the Pink Sheets. Our recommendation is biased, we have an interest in an trading account with GATA free trading stock and we are paid to perform financial consulting services for GATA, including this report, and we have elected to take our compensation in GATA stock. We reserve the right to sell this stock at any time without further notice.

John Lux of Investing-performance.com has received compensation for financial consulting work for the company and expects to receive such compensation in the future. Such compensation may be paid in cash or stock. John Lux and or www.investing-performance.com may receive payments from the issuer for financial advice or investment banking services rendered. John Lux’s and www.investing-performance.com’s mandate here is simply to provide accurate coverage of the issuer to its shareholders and followers. Go to http://www.investing-performance.com right now and follow this company coverage.

Never invest in any stock featured on our site, emails or press releases unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site. The investing-performance.com employees are not Registered as Investment Advisors in any jurisdiction whatsoever.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. investing-performance.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and www.investing-performance.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. investing-performance.com and its affiliates are not registered investment advisors or broker dealers. investing-performance.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. investing-performance.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. investing-performance.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through investing-performance.com. investing-performance.com owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company’s actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company’s products, the company’s ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information: investing-performance.com may provide hyperlinks to third party websites or access to third party content. investing-performance.com does not control, endorse, or guarantee content found in such sites. You agree that investing-performance.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that investing-performance.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

For further information, please contact: http://www.investing-performance.com and Lux.investor@gmail.com

Groupe Athena Inc.

OTC Pink: GATA

______

Our Recommendation: Strong Speculative Buy

We strongly recommend buying GATA for suitable speculative accounts but only for those traders who are experienced and sophisticated enough to handle the volatile trading that is likely to occur in GATA, which is a Pink Sheet company with tiny float.

We envision that Competition for this stock at current prices will be very strong.

We believe that GATA has unrecognized growth potential and that buying the stock at these prices offers limited downside risk and a chance to participate in the large and rapid growth potential of GATA.

At the present time, we believe GATA has first mover, geographical and technical advantages in a huge, fast growing market and its growth for the next few years will only be limited by its ability to expand internally. This is further proven by the strong growth by GATA to date. After GATA’s start less than three years ago with sales by GATA are up 300% in two years.

The more you look at our earnings model for GATA, the more you can find yourself solidly grasping the future potential buying GATA stock now. GATA may continue its near 100% annual growth rate and 10% net earnings ratio for the next few years due to an explosion in a market where it has a strong geographical advantages, first mover advantages, and technical advantages.

Taking all this into account causes you to start to understand why GATA has exceptional potential. As we envision a time a few years from now when GATA has compounded its exponential growth, and we have participated in this action, we believe that we can then look back on the GATA stock price today as a fraction of its true worth. This is why look in overlooked markets for overlooked stocks; we want to find exciting stocks that we are eager to buy before they are discovered by the crowd.

The Company

Groupe Athena (GATA) helps companies in India and South East Asia to get United States Food and Drug Administration (FDA) approval in the United States for pharmaceuticals and medical products and devices for sale in the United States. This opens the huge U.S. Market to these Indian and South East Asian drug companies.

The more you look at the services offered by GATA, the more you can see GATA’s sales and profits are growing so rapidly. GATA services help clients pass FDA inspection. Services offered by GATA include assisting them from concept through development, and consultation through all the regulatory requirements, filings, and processes to achieve United States FDA compliance and approval.

From concept through final approval, GATA navigates companies through every requirement of the process including pharmaceutical consulting, development, and regulatory compliance to achieve FDA approval. This helps their clients export pharmaceuticals, medical products and medical equipment to the USA.

GATA has offies in India and America. GATA can go to American target companies and U.S. regulatory authorities directly. GATA can also consult easily with clients in the large, fast growing markets in the East, India and South East Asia, and provide complete consulting services for FDA compliance. GATA’s dual locations in India and America give GATA significant geographical advantage.

Services offered by GATA include technical and regulatory consulting for biotechnical products, pharmaceuticals (over the counter, prescription and generics), diagnostics, medical equipment, and devices.

GATA Services

Foreign drug and medical companies find the FDA inspection process complicated, especially when they are trying to export to the U.S. There is a broad spectrum of consulting and assistance offered by GATA. These services are vital to get its clients through the FDA inspection process.

The importance of these services to GATA’s clients would be hard to overestimate. Professional consulting by GATA reduces the risk of having products rejected and incurring increased expenses and the additional expense of delay which can often result in competitive disadvantage. GATA also offers follow-through on steps necessary for FDA compliance and identifying and solving breaches in compliance. A breach in compliance can bring huge losses, delays and more competitive disadvantages. Thus, GATA’s client are highly motivated to put a high value on the services offered by GATA.

Seeking FDA approval can be frustrating and disappointing if not done right. GATA strives to provide the highest quality services and the most positive outcomes at the least expense to clients.

In India and South East Asia, GATA has unmatched knowledge of the FDA approval process, as well as experience and knowledge of the Indian and South East Asian cultures in which GATA conducts business.

GATA offers an initial consultation to enable planning and strategizing by GATA with goals specific to client product or company needs. GATA delivers comprehensive consulting throughout the inspection process including mock FDA inspections and mock product recalls to identify and solve breaches in compliance. With the right knowledge about supplier audits, document preparation and filing processes, GATA is able to meet all regulations and requirements. Guidelines are also provided by GATA to ensure quality throughout development.

Large Indian Market

The more you examine the size and growth of GATA’s market, the more you find yourself excited by its potential. GATA serves a large market: Indian and East Asian drug companies. The Indian pharmaceutical industry is the world’s second-largest by volume. India’s bio-tech industry grew 17% with revenues of $3 billion in the 2009-10 financial year over the previous fiscal year. Indian companies have a niche in both the Indian and world markets with their expertise in reverse-engineering new processes for manufacturing drugs at low costs.

In terms of the global market, India currently holds a modest 1-2% share, but it has been growing at approximately 10% per year. India gained its foothold on the global scene with its innovatively-engineered generic drugs and active pharmaceutical ingredients (API). India is now seeking to become a major player in outsourced clinical research as well as contract manufacturing and research. There are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other country outside the U.S.

Both the Indian central and state governments have recognized R&D as an important driver in the growth of their pharma businesses and conferred tax deductions for expenses related to research and development. As you can vividly imagine, these types of incentives naturally help GATA. The government has granted other concessions as well, such as reduced interest rates for export financing and a cut in the number of drugs under price control. Government support is not the only thing in Indian pharma’s favor; companies have access to a highly developed IT industry that help in important new molecule discovery.

India also boasts of a well-educated, English-speaking labor force that is the base of its competitive advantage. Although molecular biologists are in short supply, there are a number of talented chemists who are equally as important in the discovery process. In addition, there has been a reverse brain drain effect in which scientists are returning from abroad to accept positions at lower salaries at Indian companies. Once there, these foreign-trained scientists can transfer the benefits of their knowledge and experience to all of those who work with them.

Expertise

GATA has 15 consultants in offices in America and India offering the highest quality assistance to Indian and South East Asian pharmaceutical and medical companies seeking FDA approval for their products to export to the U.S. These expert consultants include three PhDs, nine pharmacists, two MBAs and an attorney to provide a good knowledge of FDA rules and regulations, pharmaceutical knowledge and the cornerstones to secure FDA approval for GATA clients.

GATA’s founders are all Indians. GATA has a reputation for being the first choice for FDA regulatory consultancy in its region and for its ability to understand the obstacles and complications for Indian and South East Asian companies, as well as the requirements that would be expected by the Food and Drug Administration in America.

GATA understands the values and the language. GATA’s experience and education on the subject matter, together with an absolute focus on client satisfaction and support, has made GATA a leader in the large, fast growing markets of India and South East Asia in the field of FDA consultancy. This has provided the outstanding growth in revenues and strong profit margins accomplished by GATA. GATA also has a laboratory facility located in India to assist with testing and clinical trials for GATA clients.

Large, Growing Market

Understanding the large, growing market for GATA’s customers causes you to see the exciting future growth that is out there for GATA. Manufacturing drugs in India is much cheaper in than in the United States, giving Indian and South East Asian drug manufacturers advantages to selling in the United States, as well as giving them an incentive to use the services provided by GATA and its experts.

Information provided by GATA now tells us that right now about $11 billion in drugs are being sent from India to the U.S. each year. However, market estimates by GATA now indicate that in the next five years there will be as much as $40 billion sent to the U.S. from India. By considering this growth in sales of drugs from India to the United States, you can start to imagine just how much more of a demand there will be for all the services offered by GATA. Consider also that these drugs and medical products have notoriously high profit margins, especially in low cost production in India and South East Asia. This means that GATA’s customers can afford to pay GATA generously for all the services provided to them by GATA.

We believe that for the next three years GATA will have clear field to grab new business with its first mover advantages, technical advantages, and geographical advantages in the Indian and East Asian markets.

Competitive Advantages

While there are many companies in the United States that can assist bio-tech and pharmaceutical companies in working their way through the U.S. Food and Drug Administration, there are few such companies competing with GATA in India or Asia and GATA has the first mover advantage there.

As of 2008, the FDA required such companies to be U.S.-based. GATA is based in New Jersey but has service facilities in India. Thus, GATA understands the large and expanding Indian and South East Asian markets and does not have to travel half-way around the world to visit clients, as would competitors based only in the U.S. GATA “speaks the language” of its Indian and South East Asian clients. The more you consider the importance of all this, the more you can see that GATA has stable and unique competitive advantages.

Overlooked Penny Stock Opportunity

GATA is a penny stock that has recently started trading in the Pink Sheets. As a recently listed stock in an overlooked market, GATA has not had an opportunity to attract the kind of attention that would cause GATA to be fully priced. We believe that this is the reason GATA is such a bargain. We envision a situation where not only will the volume and price of GATA stock be propelled by its strong competitive position in an explosive growth market, increased interest in the stock will bring increased volume and marketability. With this increased marketability will come improving price/earning ratios. Thus, GATA’s stock price will not only benefit from its rapidly growing sales and earnings, those who buy GATA now will benefit from price-earnings multiple expansion as the company becomes more well known and actively traded. Experience tells us that such small companies have a way of exploding as they become more well known.

Trading – Huge Spread

This is a small cap stock with a market cap of $24 million even at the last sale price, which is the current high price – meaning that GATA is selling at less than on times projected revenues and less than ten times the earnings we estimate for the end of its fiscal year this June in less than two months.

GATA’s float is tiny – only a little over two million shares. At the bid, the float has a total value of only about $1.2 million. There are a mere 39 shareholders that we know of. We expect large spreads and intense trading in this stock.

When you understand the upside volatility of a float this thin, and add the excitement that can be created when traders clearly envision that growth potential of GATA, you can see why traders who find themselves eager to grab this opportunity can bid the price up rapidly.

In a fast growth stock like GATA, with this unusual potential, the decision to buy is easy. What is a challenge is buying the stock in quantity as is the supply of stock in the float and volume of stock offered are both very scarce. Inevitably, there will be more demand than supply and aggressive traders will compete to get stock. There will be winners in this battle and losers. The winners will profit and the losers will lose out. Your trading skill and aggression will determine your result. We simply predict that a year from now, a stock like GATA will sell at much higher prices and our earnings model, which follows below, will show you why.

Earnings Model – Company Valuation

When you take a look at these revenue and earnings tables below, you can start to get a feeling for the energy in this earnings model. (Note that the periods presented are for each six months, not quarterly periods.)

The results created by GATA clearly cause you to perceive that GATA has proven its accelerating upward trajectory. GATA started operations in July 1, 2008 and recorded $2.4 million revenues in the first six months alone, even though it was a start up company. This shows you that GATA’s customers are eager to buy large amounts of its services. The continuing revenue and earnings growth by GATA shows you that these clients like GATA and are eager to buy more GATA services now.

Revenues from the six months ended December 31, 2010 compared with the revenues of the first six months in 2008, are up over 300% in two years. The more you look at this type of growth, the more you can find yourself placing GATA in that spot in your mind where you put high growth companies that you have to have in your portfolio now. Adding to the potential, GATA’s profit margins, discounting the start up period, average out at 10%, showing us GATA’s ability to maintain prices and profits due to its technical expertise, geographical advantages, and first mover advantages.

If GATA grows at its current rate and reaches $25 million in revenues in the 2011 fiscal year ending in a few weeks in June 2011 as GATA predicted in the notes to its financial statements dated June 30, 2010, GATA will have net income of an estimated $2.5 million, or over $0.05 per share. At a growth P/E of 20 times earnings, GATA could sell over $1.00. This may account for the recent price uptick by GATA stock.

We believe it is easy to see another three years of uninhibited growth for GATA due to GATA’s first mover, technical and geographical advantages in its large and rapidly growing markets. While we are not saying that you can predict the future two years from now with total confidence, and we do not believe that all such predictions can be relied upon, and we do not maintain that we have a crystal ball despite GATA’s market position and exceptionally consistent growth and profitability to date, we would like to point out that if GATA grows at its current rate of about 100% per year, naturally the price will move up rapidly as more and more investors discover the stock and buy GATA.

A year to year comparison with projections shows this growth and its potential even more dramatically:

(1) Based on current outstanding shares of 47,136,900.

Risks

Every growth company has risks. Growth itself can create problems for companies, and the faster the growth, the larger the problems. We believe that GATA’s growth for the next few years is limited only by its ability to attract talented key employees and create supporting infrastructure. Being in a market where your customers are selling $3 billion in products per year that will grow to a predicted $30 billion in sales for these customers in the U.S. market for the next five years, will create strains on the company.

Typical risks for companies of this kind include larger competitors entering the market, loss of key personnel, loss of reputation, regulatory sanctions and changes in regulations.

Another risk factor is the presence of the company in the Pink Sheet marketplace which is notorious for its predatory short sellers and market manipulation.

We do not believe that share dilution is a risk as we believe that GATA has sufficient cash flow to finance its expansion as GATA has a relatively low level of capital expenditures. Management has assured us that there will no dilution for at least two years.

As quantitative analysts (of which I am one) will tell you, there are actually two risks in any decision. First is the risk that everyone knows, the risk that you take action and are wrong. Second is the hidden and usually overlooked risk that you are right and fail to take action. As I have so often said, “Theory without nerve doesn’t lead to action — and in the stock market, it’s action that makes you money.”

The limited float in GATA, along with the huge spread, will also produce violent price fluctuations and limited volumes to buy and sell stock. This is only for sophisticated traders who can take advantage of explosive and volatile situations.
Recommendation

GATA is an overlooked, fast growing company with technical, geographical and first mover advantages in the fast growing Indian and South East Asian pharmaceutical and medical markets. We believe GATA is a unique, long-term speculation for small penny stock players. The Company has a strong business model, strong earnings, and seemingly unlimited growth potential. Please note, we have an interest in the stock of this company, see Disclaimers.
Disclaimers

This is a very speculative stock traded at in the Pink Sheets. Our recommendation is biased, we have an interest in an trading account with GATA free trading stock and we are paid to perform financial consulting services for GATA, including this report, and we have elected to take our compensation in GATA stock. We reserve the right to sell this stock at any time without further notice.

John Lux of Investing-performance.com has received compensation for financial consulting work for the company and expects to receive such compensation in the future. Such compensation may be paid in cash or stock. John Lux and or www.investing-performance.com may receive payments from the issuer for financial advice or investment banking services rendered. John Lux’s and www.investing-performance.com’s mandate here is simply to provide accurate coverage of the issuer to its shareholders and followers. Go to http://www.investing-performance.com right now and follow this company coverage.

Never invest in any stock featured on our site, emails or press releases unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site. The investing-performance.com employees are not Registered as Investment Advisors in any jurisdiction whatsoever.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. investing-performance.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and www.investing-performance.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. investing-performance.com and its affiliates are not registered investment advisors or broker dealers. investing-performance.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. investing-performance.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. investing-performance.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through investing-performance.com. investing-performance.com owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company’s actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company’s products, the company’s ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information: investing-performance.com may provide hyperlinks to third party websites or access to third party content. investing-performance.com does not control, endorse, or guarantee content found in such sites. You agree that investing-performance.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that investing-performance.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

For further information, please contact: http://www.investing-performance.com and Lux.investor@gmail.com

The instant and important question for the investor, or the short seller, is how big are the damages? Are these lawsuits significant in comparison to LPS’ $2.3 billion market value?
The answer is that the damages are enormous and we envision LPS dropping another 15 points at least. LPS processed enough defaulted mortgages in 2010 alone to rack up over $1 billion in revenues. We suspect that there was a relatively high percentage of fraudulent cases. The damages to a homeowner who was improperly foreclosed on are at least the rent he would have to pay to occupy new property, moving expenses, damages to his credit. We would estimate $20,000 easily for each plaintiff, whether or not they had equity in their house at the time of foreclosure. If 10% of the cases involved fraud, then potential damages could be $20 billion. While the plaintiffs are likely to settle for less, we expect the damage inflicted to LPS to be significant any way you look at it.

To that you can add damages for the lawsuits based on securities fraud for non-disclosure and fraudulent disclosure.

We do not expect LPS to survive in its current state of health or anywhere near it, even if the plaintiffs’ attorneys are lenient.

By John Lux and Alex Morfesis  – we have no position in this stock now but may initiate positions.

Subscribe now to discover more secrets of a professional stock trader!

Buy my books on Amazon – How to Find a Home Run Stock and How to Pick Hot Reverse Merger Penny Stocks